Semaglutide trial investigates albuminuria and kidney function changes in Type 1 Diabetes
Background
Diabetic kidney disease (DKD) is a severe complication of both Type 1 and Type 2 Diabetes, leading to progressive kidney damage and increased cardiovascular mortality. While GLP-1 receptor agonists (GLP-1RAs) like semaglutide have shown significant renoprotective benefits in Type 2 Diabetes, their role in Type 1 Diabetes (T1D) is less established. Mechanistic studies suggest a GLP-1-mediated gut-kidney crosstalk, where GLP-1 exerts a natriuretic action, expanding extracellular fluid volume and potentially improving renal hemodynamics. This trial aims to explore if these benefits extend to the unique pathophysiology of T1D-associated kidney disease, addressing a critical gap in current treatment strategies.
Study Design
This is a recruiting, randomized, placebo-controlled clinical trial (NCT05819138) in individuals with Type 1 Diabetes. Participants will receive either semaglutide via pen injector or placebo for a duration of 26 weeks. The primary objective is to determine the change in albuminuria from baseline to 26 weeks. Secondary objectives include assessing changes in kidney parameters, specifically kidney oxygenation and function, measured by MRI from baseline to 26 weeks. Other objectives encompass evaluating the glycemic effects and safety profile of semaglutide in this population. The study is sponsored by the University of Colorado, Denver, and is anticipated to complete by December 2027.
Results
This is a currently recruiting clinical trial, and as such, no findings or results are available yet. The study aims to generate crucial data on the potential renoprotective, glycemic, and safety effects of semaglutide in individuals with Type 1 Diabetes. Researchers will specifically analyze changes in albuminuria, a key biomarker for diabetic kidney disease progression. Furthermore, advanced MRI techniques will be employed to quantify alterations in kidney oxygenation and overall kidney function, providing a deeper mechanistic understanding beyond traditional markers. The trial's completion in late 2027 will provide the first insights into these specific outcomes. > The primary endpoint is the change in albuminuria from baseline to 26 weeks, with secondary endpoints focusing on kidney oxygenation and function via MRI.
Key Findings
- Trial is actively recruiting participants with Type 1 Diabetes.
- Primary endpoint: change in albuminuria from baseline to 26 weeks.
- Secondary endpoints: changes in kidney oxygenation and function via
MRI. - Glycemic effects and safety profile of semaglutide are also being assessed.
- Results are anticipated after the trial's completion in December 2027.
Why It Matters
If this trial demonstrates positive results, it could fundamentally alter the management of diabetic kidney disease in Type 1 Diabetes. Currently, GLP-1RAs are not standard therapy for kidney protection in T1D, unlike in T2D. A successful outcome would provide strong evidence for incorporating semaglutide into treatment protocols for T1D patients at risk of or with established kidney complications, potentially slowing disease progression and improving long-term outcomes. This could lead to a new off-label or eventually approved indication, expanding the utility of semaglutide beyond glycemic control and weight management in this population. The use of MRI for kidney oxygenation also offers a novel, non-invasive way to monitor treatment efficacy, potentially guiding future personalized medicine approaches.
semaglutide
type-1-diabetes
diabetic-kidney-disease
albuminuria
renal-protection
clinical-trial